Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Latest news
-
-
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
-
Advancing siRNA Drug Discovery and Development with AI
Advancing siRNA Drug Discovery and Development with AI
-
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
-
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
-
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia.
-
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
Contacts
-
Julia Grönros Press contact Project Director External Innovation julia.gronros@ribocure.com +46 73 094 61 08
-
John Taylor Press contact Global Head of Business Development john.taylor@ribocure.com + 46 73 275 96 04
